
    
      OBJECTIVES:

        -  Determine the response rate in younger patients with recurrent or refractory Ewing's
           sarcoma treated with cytarabine.

      OUTLINE: This is a multicenter study.

      Patients receive cytarabine IV over 2 hours twice daily on days 1-5. Treatment repeats every
      21 days for up to 11 courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed periodically for 5 years.

      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
    
  